Audun Osland Vik-Mo

Audun Osland Vik-Mo

Auto-generated profile, based on publicly available information

Audun Osland Vik-Mo

Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2005 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
JFJ Fernø
J Fernø
MRM B Raeder
M B Raeder
AVA O Vik-Mo
A O Vik-Mo
SSS Skrede
S Skrede
MGM Glambek
M Glambek
VSV M Steen
V M Steen

6 July 2018 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
AVAudun Osland Vik‐Mo
Audun Osland Vik‐Mo
LGLasse Giil
Lasse Giil
CBClive Mr. Ballard
Clive Mr. Ballard
DADag Aarsland
Dag Aarsland

30 October 2008 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
JFJohan Fernø
Johan Fernø
AVAudun O. Vik-Mo
Audun O. Vik-Mo
GJGoran Jassim
Goran Jassim
BHBjarte Håvik
Bjarte Håvik
KBKjetil Berge
Kjetil Berge
VSVidar M. Steen
Vidar M. Steen

23 May 2006 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MRMaria B. Raeder
Maria B. Raeder
JFJohan Fernø
Johan Fernø
AVAudun O. Vik-Mo
Audun O. Vik-Mo
VSVidar M. Steen
Vidar M. Steen

11 September 2019 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
AVAudun Osland Vik-Mo
Audun Osland Vik-Mo
LGLasse Melvaer Giil
Lasse Melvaer Giil
MBMiguel Germán Borda
Miguel Germán Borda
CBClive Ballard
Clive Ballard
DADag Aarsland
Dag Aarsland
Introduction: Understanding the natural course of neuropsychiatric symptoms (NPS) in dementia is important for planning patient care and trial design, but few studies have described the long-term course of NPS in individuals.Method: Primary inclusion of 223 patients with suspected mild dementia from general practice were followed by annual assessment, including the Neuropsychiatric Inventory (NPI), for up to 12 years. Total and item NPI scores were classified as stable, relapsing, single episodic or not present based on 4.96 (s.d. 2.3) observations (98% completeness of longitudinal data) for 113 patients with Alzheimer's disease and 84 patients with LBD (68 dementia with Lewy bodies and 16 Parkinson's disease dementia).Results: We found that 80% had stable NPI total ≥1, 50% had stable modest NPI total ≥12 and 25% had stable NPI total ≥24 scores. Very severe NPS (≥48) were mostly single episodes, but 8% of patients with Alzheimer's disease had stable severe NPS. Patients with Alzheimer's disease and the highest 20% NPI total scores had a more stable or relapsing course of four key symptoms: aberrant motor behaviour, aggression/agitation, delusions and irritability (odds ratio 55, P < 0.001). This was not seen in LBD. Finally, 57% of patients with Alzheimer's disease and 84% of patients with LBD had reoccurring psychotic symptoms.Conclusions: We observed a highly individual course of NPS, with most presenting as a single episode or relapsing; a stable course was less common, especially in LBD. These findings demonstrate the importance of an individualised approach (i.e. personalised medicine) in dementia care.

20 October 2006 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
JFJohan Fernø
Johan Fernø
SSSilje Skrede
Silje Skrede
AVAudun O Vik-Mo
Audun O Vik-Mo
BHBjarte Håvik
Bjarte Håvik
VSVidar M Steen
Vidar M Steen
The etiology of schizophrenia is unknown, but neurodevelopmental disturbances, myelin- and oligodendrocyte abnormalities and synaptic dysfunction have been suggested as pathophysiological factors in this severe psychiatric disorder. Cholesterol is an essential component of myelin and has proved important for synapse formation. Recently, we demonstrated that the antipsychotic drugs clozapine and haloperidol stimulate lipogenic gene expression in cultured glioma cells through activation of the sterol regulatory element-binding protein (SREBP) transcription factors. We here compare the action of chlorpromazine, haloperidol, clozapine, olanzapine, risperidone and ziprasidone on SREBP activation and SREBP-controlled gene expression (ACAT2, HMGCR, HMGCS1, FDPS, SC5DL, DHCR7, LDLR, FASN and SCD1) in four CNS-relevant human cell lines. There were marked differences in the ability of the antipsychotic drugs to activate the expression of SREBP target genes, with clozapine and chlorpromazine as the most potent stimulators in a context of therapeutically relevant concentrations. Glial-like cells (GaMg glioma and CCF-STTG1 astrocytoma cell lines) displayed more pronounced drug-induced SREBP activation compared to the response in HCN2 human cortical neurons and SH-SY5Y neuroblastoma cells, indicating that antipsychotic-induced activation of lipogenesis is most prominent in glial cells. Our present data show a marked variation in the ability of different antipsychotics to induce SREBP-controlled transcriptional activation of lipogenesis in cultured human CNS-relevant cells. We propose that this effect could be relevant for the therapeutic efficacy of some antipsychotic drugs.